Literature DB >> 32325142

Janus kinase inhibition in complement component 1 deficiency.

Christine Wolf1, Normi Brück1, Sarah Koss1, Constanze Griep1, Michael Kirschfink2, Katharina Palm-Beden3, Mingyan Fang4, Nadja Röber5, Stefan Winkler1, Reinhard Berner1, Eike Latz6, Claudia Günther7, Min Ae Lee-Kirsch8.   

Abstract

Entities:  

Year:  2020        PMID： 32325142     DOI： 10.1016/j.jaci.2020.04.002

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  4 in total

Review 1.  The yin and the yang of early classical pathway complement disorders.

Authors:  Kathleen E Sullivan
Journal:  Clin Exp Immunol       Date:  2022-08-19       Impact factor: 5.732

2.  Primary Sjögren's syndrome and high type I interferon signalling in a kindred with C2 deficiency.

Authors:  Mathijs Willemsen; Erika Van Nieuwenhove; Nasim Sadat Seyed Tabib; Frederik Staels; Rik Schrijvers; Lien De Somer; Adrian Liston; Stephanie Humblet-Baron; Carine Wouters
Journal:  Rheumatol Adv Pract       Date:  2022-03-21

3.  Precision treatment of Singleton Merten syndrome with ruxolitinib: a case report.

Authors:  Philip Broser; Ursula von Mengershausen; Katrin Heldt; Deborah Bartholdi; Dominique Braun; Christine Wolf; Min Ae Lee-Kirsch
Journal:  Pediatr Rheumatol Online J       Date:  2022-04-11       Impact factor: 3.054

4.  Curative Treatment of POMP-Related Autoinflammation and Immune Dysregulation (PRAID) by Hematopoietic Stem Cell Transplantation.

Authors:  Andrea Meinhardt; Paula C Ramos; R Jürgen Dohmen; Nadja Lucas; Min Ae Lee-Kirsch; Benjamin Becker; Jan de Laffolie; Tomás Cunha; Tim Niehues; Ulrich Salzer; Ayami Yoshimi; Miriam Erlacher; Anke M J Peters; Stephan Ehl; Brigitte Strahm; Carsten Speckmann
Journal:  J Clin Immunol       Date:  2021-06-16       Impact factor: 8.317
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.